I am expecting big things from VIVK, put it on alert now

14
Dec

Biotechnology/Pharma is often a difficult sector for me to write on and members to understand. The complex nature of both medicines and medical devices makes it a challenge. Once you understand the science, then you have to factor in the impact of FDA clinical trials to fully quantify the opportunity that a biotech company offers.

Today’s alert company actually has a very clear path that it lays out for investors to understand: Vivakor, Inc. (VIVK)

VIVK has an astonishing breadth and depth of products, technologies and intellectual property. It conducts research in four primary areas of medical and biotechnological development:

Molecular medicine
electro-optics
biological handling
and natural and formulary compounds (i.e. nutraceuticals)

Vivakor states that they have a “hub and spoke” business model where VIVK corporate is the “engine” that drives development under the competencies that the company has. Once a product is ready for market, VIVK will select the best mode to commercialize the product that will mean the highest value to the company. Those options include:

Product Licensing and joint ventures with manufacturers, marketing/distribution partners
Outright sale of the technology
Technology spin‐off in a subsidiary where the product will be manufactured, marketed and sold directly to customers and clients.

The company has (at last count) over 12 products in various stages of FDA approval (with the related patents filed and patent-pending).

Products under Phase III clinical trails:

VivaThermic Vials for cryopreservation
VivaBlend for antioxidant supplements.

Products under Phase II clinical trails:

CryoKeeper/Carrier, a device for the storage and transport of specimens at cryogenic temperatures
VivaSight, a digital photorefractor for children’s vision screening
VivAuris, a device for middle ear redness detection
VivaGlobin, a device for anemia and cutaneous hemoglobin detection
RejuviJam, which is a jam and jelly with antioxidants and bone and cartilage supplements
SLICES, a magnetic resonance imaging enhancement software.

Products under Phase I clinical trails

Vivaplate, a microplate for rapid temperature response
VivaCycler, a heating and cooling device
Cryopsy, a device for cryogenic biopsy collection of visceral lesions
VivaGastroProtect, which are fruits and vegetables extract for the protection of digestive system
VivaCrop, a vegetation health monitor
Clinical Biomolecular Sensor - an in vitro diagnostic device used at the point of care. It also provides contract research and development services in molecular biology, device engineering, and other areas

Several products are showing great promise for near term, significant revenue:

1. Vivathermic Vials, a specialized cryovial that accommodates an improved method of cryopreservation of cells, blood, and other bio-materials, management belives could capture up to 1.5% of the $1.9 billion market for laboratory bioconsumables by 2011 and industry leading distributors anticipate a 3% annual growth in cryovial sales segment.
2. Vivaslices, a software upgrade to older MRI units that allow the unit to achieve HIGHER RESOLUTION using a patented algorithm, would be a strong entry in a $300 million market.
3. VivaSight, a device designed to modernize screening of pre-verbal and pre-literate children for ocular disorders. Ocular screening is increasingly being mandated by state governments prior to enrollment in the public school system. Management estimates that once this device is sales ready it could generate up to $150 Million for the company over a 5 year period.
4. VivaBlend, a proprietary blend of more than 18 different sources of phytochemical extracts from antioxidant rich bioactive fruits and vegetables tested by the USDA that can be added to many consumer foods, drinks and nutraceuticals as a convenient daily source of important antioxidants and other critical bioactive phytochemicals.

VivaBlend has successfully made the transition from concept to product. VIVK recently announced that it has received a $5 million licensing and purchase agreement for its Nutraceutical products from Regenca International.

Regeneca shall be the exclusive worldwide direct-to-consumer distributor for the current formulation as well as any future nutraceutical formulations offered to Regeneca by Vivakor. Regeneca has committed to purchase from Vivakor a minimum of $5 million in product over the next three years and Vivakor will receive a 15% ownership interest in Regeneca’s outstanding common stock and will be the exclusive supplier of the licensed product to Regeneca.

The full press release can be accessed by Clicking Here.

All of these products are explained (in much greater detail) on Vivakor’s corporate website: Vivakor.com There is also a corporate presentation that is “nested” on the site that has some great information, too. Corporate Presentation

To The Chart!

VIVK is doing so many things right and that impresses me. It is one of the easiest to understand biotech companies that I have ever seen. I think that VIVK should be on my members’ radar screen for the short-term appreciation as well as the long-term.

Do your due diligence. If you trade it, remember to use appropriate stop losses on the stock and take profits when you’re comfortable.

Good luck and good trading
______________________________________________________________________________

Category : Daily Soup

About Us

Traders make huge profits from penny stocks! Our Hot stock alerts are sent the second we identify likely stocks that we feel will fly! We are passionate about small caps, penny stocks and sub-penny stocks. We are the resource that you need to profit from penny stocks. Bookmark us and check back frequently. Read more »

Subsribe via RSS Feed Reader

or Subscribe via Email

Contact Us

InvestorSoup.com
4828 S. Broadway #182 | Tyler, TX 75703